Compare MKS Instruments (MKSI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MKS Instruments vs Novavax Inc — how do they compare? MKS Instruments trades at $268.04 (market cap $17.95B), while Novavax Inc trades at $9.9 (market cap $1.68B). The key difference: MKS Instruments is far larger — about 10.7× Novavax Inc's market cap, and MKS Instruments pays a 0.38% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| MKSI | NVAX | |
|---|---|---|
Market Cap | $17.95B | $1.68B |
Sector | Technology | Health |
52-Week High | $444.80 | $11.19 |
52-Week Low | $110.60 | $6.22 |
Enterprise Value | $21.53B | $1.26B |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MKS Instruments
MKS develops instruments, systems, and process control solutions for advanced manufacturing. Its technologies serve semiconductor manufacturing, electronics and packaging, photonics, and specialty industrial applications.
Read more on MKSI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
